Understanding immune-triggered inflammatory arthritis from cancer immunotherapy
Official title: Investigating clinical heterogeneity in immune checkpoint inhibitor-induced inflammatory arthritis
Funded at Johns Hopkins University · NIH-11365141 · Data updated 2026-11-12
A clinical study looks at why inflammatory arthritis caused by cancer immunotherapy affects people differently and how to best treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 2, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $569,402 |
| NIH project number | 1R01AR085636-01A1 |
| Project ID | NIH-11365141 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults receiving cancer immunotherapy who develop inflammatory arthritis as an adverse event.
✕Less likely to help
Patients without inflammatory arthritis from cancer immunotherapy are unlikely to benefit.
What this research studies
This project uses data from RADIOS, the first multicenter US observational cohort of rheumatic adverse events from cancer immunotherapy, to understand variability in disease course and treatment responses. Researchers will examine baseline patient features, disease activity, and initial steroid-sparing treatment choices to guide better, safer therapies. The goal is to improve joint outcomes while minimizing effects on cancer control. The study is conducted across multiple academic sites, led by Johns Hopkins University.
Why it matters
Potential benefit: If successful, patients could receive more personalized and safer treatment for ICI-induced inflammatory arthritis, reducing joint damage and simplifying therapy.
How similar studies have gone: This is the first prospective multicenter US cohort specifically focusing on ICI-induced inflammatory arthritis, with related work showing insights from observational rheumatic irAEs.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Cappelli, Laura Christine — Johns Hopkins University
- Study coordinator: Cappelli, Laura Christine
Related research
Other NIH-funded projects on the same topics.
-
ctDNA biomarker to guide safety of cancer immunotherapy in inflammatory arthritis
A patient-facing biomarker study using a blood test to detect tumor DNA in people with cancer who develop inflammatory arthritis from immunotherapy, to help doctors pick safer treatment choices.
-
Understanding immune changes in arthritis caused by cancer treatments
This study is looking at how a cancer treatment called immune checkpoint inhibitors might cause joint pain and inflammation in some patients, and it aims to understand how the immune system, especially certain immune cells, is involved in this process to help improve care for those affected.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Antenatal DMARD Use and Mother-Child Health in Women with Chronic Inflammatory Arthritis
This project aims to understand how continuing pregnancy-safe arthritis medicines during pregnancy affects health outcomes for mothers with chronic inflammatory arthritis and their babies.
-
Gut barrier and antibiotics: how gut health affects inflammatory arthritis
Antibiotic use may increase the risk of inflammatory arthritis by changing the gut, and this project looks at how those gut changes influence joint inflammation in people with arthritis.
-
Setbp1’s role in how joint cells behave during inflammatory arthritis
This project looks at how a protein called SETBP1 affects delicate joint cells (FLS) that drive inflammation in arthritis, with potential implications for better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.